(Q34324440)

1 August 2017

0 references

1 reference

title

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies (English)

1 reference

1 August 2017

0 references

1 reference

6

1 reference

1 August 2017

M Ferwana

1

1 reference

1 August 2017

B Firwana

2

1 reference

1 August 2017

R Hasan

3

1 reference

1 August 2017

M H Al-Mallah

4

1 reference

1 August 2017

S Kim

5

1 reference

1 August 2017

M H Murad

7

1 reference

1 August 2017

publication date

1 September 2013

1 reference

1 August 2017

1 reference

1 August 2017

volume

30

1 reference

1 August 2017

issue

9

1 reference

1 August 2017

page(s)

1026-1032

1 reference

Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).

1 August 2017

cites work

1 reference

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes

21 January 2018

1 reference

Earlier triple therapy with pioglitazone in patients with type 2 diabetes.

21 January 2018

1 reference

Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials

21 January 2018

1 reference

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens

21 January 2018

1 reference

Metformin and pioglitazone: Effectively treating insulin resistance

21 January 2018

1 reference

A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat.

21 January 2018

1 reference

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

21 January 2018

1 reference

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

21 January 2018

1 reference

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

21 January 2018

1 reference

Pioglitazone and bladder cancer: a population-based study of Taiwanese.

21 January 2018

1 reference

Association between smoking and risk of bladder cancer among men and women

21 January 2018

1 reference

Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

21 January 2018

1 reference

Cancer risks in thiazolidinedione users compared to other anti-diabetic agents

21 January 2018

1 reference

Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

21 January 2018

1 reference

Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

A Case for Clarity, Consistency, and Helpfulness: State-of-the-Art Clinical Practice Guidelines in Endocrinology Using the Grading of Recommendations, Assessment, Development, and Evaluation System

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DME.12144

1 reference

1 August 2017

1 reference